tiprankstipranks
Sarepta Therapeutics Inc. (SRPT)
NASDAQ:SRPT
US Market
SRPT
Sarepta Therapeutics
RESEARCH TOOLSreports

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

4,059 Followers
See the Price Targets and Ratings of:

SRPT Analyst Ratings

Hold
25Ratings
Hold
7 Buy
13 Hold
5 Sell
Based on 25 analysts giving stock ratings to
Sarepta
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SRPT Stock 12 Month Forecast

Average Price Target

$21.33
▼(-8.18% Downside)
Based on 25 Wall Street analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $21.33 with a high forecast of $38.00 and a low forecast of $5.00. The average price target represents a -8.18% change from the last price of $23.23.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","63":"$63","18.75":"$18.75","33.5":"$33.5","48.25":"$48.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,18.75,33.5,48.25,63],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.13,23.35076923076923,24.57153846153846,25.79230769230769,27.013076923076923,28.23384615384615,29.454615384615384,30.675384615384615,31.896153846153844,33.11692307692307,34.33769230769231,35.558461538461536,36.779230769230765,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.13,22.068461538461538,22.006923076923076,21.945384615384615,21.883846153846154,21.822307692307692,21.76076923076923,21.699230769230766,21.637692307692305,21.576153846153844,21.514615384615382,21.45307692307692,21.39153846153846,{"y":21.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.13,20.81230769230769,19.494615384615383,18.176923076923075,16.85923076923077,15.54153846153846,14.223846153846154,12.906153846153845,11.588461538461537,10.270769230769229,8.953076923076921,7.6353846153846145,6.317692307692306,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":61.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.78,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.74,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 67, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 81, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 27</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.16,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 69, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 26</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":19.32,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.01,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":19.72,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.52,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20.72,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.32,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.13,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$38.00Average Price Target$21.33Lowest Price Target$5.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on SRPT
Yanan Zhu
Wells Fargo
Wells Fargo
$60→$38
Buy
63.58%
Upside
Reiterated
04/01/26
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)
WBB Securities Analyst forecast on SRPT
Unknown Analyst
WBB Securities
Not Ranked
WBB Securities
$38
Buy
63.58%
Upside
Reiterated
03/26/26
WBB Securities Remains a Buy on Sarepta Therapeutics (SRPT)
Deutsche Bank Analyst forecast on SRPT
David Hoang
Deutsche Bank
Deutsche Bank
$12→$14
Sell
-39.73%
Downside
Reiterated
03/26/26
Deutsche ups Sarepta target, says 35% stock rally overdoneDeutsche ups Sarepta target, says 35% stock rally overdone
Needham Analyst forecast on SRPT
Gil Blum
Needham
Needham
―
Sell
―
Reiterated
03/26/26
Analysts Offer Insights on Healthcare Companies: Neurogene (NASDAQ: NGNE), Vertex Pharmaceuticals (NASDAQ: VRTX) and Sarepta Therapeutics (NASDAQ: SRPT)
H.C. Wainwright Analyst forecast on SRPT
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$5
Sell
-78.48%
Downside
Reiterated
03/26/26
Sell Rating on Sarepta: Strong siRNA Muscle Exposure Undermined by Weak Clinical Validation and ELEVIDYS Sales Risk
Barclays Analyst forecast on SRPT
Eliana Merle
Barclays
Barclays
$20
Hold
-13.90%
Downside
Reiterated
03/26/26
Barclays Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)
Citi Analyst forecast on SRPT
Yigal Nochomovitz
Citi
Citi
$9→$13
Sell
-44.04%
Downside
Reiterated
03/26/26
Sarepta Therapeutics: Early TRiM Platform Promise Outweighed by High Clinical Risk and Valuation Downside, Justifying Sell Rating
Morgan Stanley Analyst forecast on SRPT
Michael Ulz
Morgan Stanley
Morgan Stanley
$20→$25
Hold
7.62%
Upside
Assigned
03/26/26
Analysts Are Neutral on Top Healthcare Stocks: Terns Pharmaceuticals (TERN), Sarepta Therapeutics (SRPT)
Wedbush Analyst forecast on SRPT
Yun Zhong
Wedbush
Wedbush
$29→$35
Buy
50.67%
Upside
Assigned
03/26/26
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Rezolute (NASDAQ: RZLT) and Demant (Other OTC: WILLF)
Leerink Partners Analyst forecast on SRPT
Joseph Schwartz
Leerink Partners
Leerink Partners
$15
Hold
-35.43%
Downside
Reiterated
03/25/26
Sarepta initial siRNA data 'thin and somewhat mixed,' says LeerinkSarepta initial siRNA data 'thin and somewhat mixed,' says Leerink
J.P. Morgan Analyst forecast on SRPT
Anupam Rama
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
03/25/26
Analysts Conflicted on These Healthcare Names: Denali Therapeutics (NASDAQ: DNLI), Sarepta Therapeutics (NASDAQ: SRPT) and Cardiff Oncology (NASDAQ: CRDF)
Bernstein Analyst forecast on SRPT
William Pickering
Bernstein
Bernstein
$20
Hold
-13.90%
Downside
Reiterated
03/25/26
Bernstein Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
Mizuho Securities Analyst forecast on SRPT
Uy Ear
Mizuho Securities
Mizuho Securities
$17.61→$31
Buy
33.45%
Upside
Reiterated
03/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (NASDAQ: PROK), LENZ Therapeutics (NASDAQ: LENZ) and Sarepta Therapeutics (NASDAQ: SRPT)
Oppenheimer Analyst forecast on SRPT
Kostas Biliouris
Oppenheimer
Oppenheimer
―
Buy
―
Reiterated
03/25/26
Sarepta early DM1 data 'appear promising,' says OppenheimerSarepta early DM1 data 'appear promising,' says Oppenheimer
Cantor Fitzgerald Analyst forecast on SRPT
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$21
Hold
-9.60%
Downside
Reiterated
03/16/26
Cantor Fitzgerald Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on SRPT
Yanan Zhu
Wells Fargo
Wells Fargo
$60→$38
Buy
63.58%
Upside
Reiterated
04/01/26
Wells Fargo Remains a Buy on Sarepta Therapeutics (SRPT)
WBB Securities Analyst forecast on SRPT
Unknown Analyst
WBB Securities
Not Ranked
WBB Securities
$38
Buy
63.58%
Upside
Reiterated
03/26/26
WBB Securities Remains a Buy on Sarepta Therapeutics (SRPT)
Deutsche Bank Analyst forecast on SRPT
David Hoang
Deutsche Bank
Deutsche Bank
$12→$14
Sell
-39.73%
Downside
Reiterated
03/26/26
Deutsche ups Sarepta target, says 35% stock rally overdoneDeutsche ups Sarepta target, says 35% stock rally overdone
Needham Analyst forecast on SRPT
Gil Blum
Needham
Needham
―
Sell
―
Reiterated
03/26/26
Analysts Offer Insights on Healthcare Companies: Neurogene (NASDAQ: NGNE), Vertex Pharmaceuticals (NASDAQ: VRTX) and Sarepta Therapeutics (NASDAQ: SRPT)
H.C. Wainwright Analyst forecast on SRPT
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$5
Sell
-78.48%
Downside
Reiterated
03/26/26
Sell Rating on Sarepta: Strong siRNA Muscle Exposure Undermined by Weak Clinical Validation and ELEVIDYS Sales Risk
Barclays Analyst forecast on SRPT
Eliana Merle
Barclays
Barclays
$20
Hold
-13.90%
Downside
Reiterated
03/26/26
Barclays Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)
Citi Analyst forecast on SRPT
Yigal Nochomovitz
Citi
Citi
$9→$13
Sell
-44.04%
Downside
Reiterated
03/26/26
Sarepta Therapeutics: Early TRiM Platform Promise Outweighed by High Clinical Risk and Valuation Downside, Justifying Sell Rating
Morgan Stanley Analyst forecast on SRPT
Michael Ulz
Morgan Stanley
Morgan Stanley
$20→$25
Hold
7.62%
Upside
Assigned
03/26/26
Analysts Are Neutral on Top Healthcare Stocks: Terns Pharmaceuticals (TERN), Sarepta Therapeutics (SRPT)
Wedbush Analyst forecast on SRPT
Yun Zhong
Wedbush
Wedbush
$29→$35
Buy
50.67%
Upside
Assigned
03/26/26
Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Rezolute (NASDAQ: RZLT) and Demant (Other OTC: WILLF)
Leerink Partners Analyst forecast on SRPT
Joseph Schwartz
Leerink Partners
Leerink Partners
$15
Hold
-35.43%
Downside
Reiterated
03/25/26
Sarepta initial siRNA data 'thin and somewhat mixed,' says LeerinkSarepta initial siRNA data 'thin and somewhat mixed,' says Leerink
J.P. Morgan Analyst forecast on SRPT
Anupam Rama
J.P. Morgan
J.P. Morgan
―
Hold
―
Reiterated
03/25/26
Analysts Conflicted on These Healthcare Names: Denali Therapeutics (NASDAQ: DNLI), Sarepta Therapeutics (NASDAQ: SRPT) and Cardiff Oncology (NASDAQ: CRDF)
Bernstein Analyst forecast on SRPT
William Pickering
Bernstein
Bernstein
$20
Hold
-13.90%
Downside
Reiterated
03/25/26
Bernstein Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
Mizuho Securities Analyst forecast on SRPT
Uy Ear
Mizuho Securities
Mizuho Securities
$17.61→$31
Buy
33.45%
Upside
Reiterated
03/25/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (NASDAQ: PROK), LENZ Therapeutics (NASDAQ: LENZ) and Sarepta Therapeutics (NASDAQ: SRPT)
Oppenheimer Analyst forecast on SRPT
Kostas Biliouris
Oppenheimer
Oppenheimer
―
Buy
―
Reiterated
03/25/26
Sarepta early DM1 data 'appear promising,' says OppenheimerSarepta early DM1 data 'appear promising,' says Oppenheimer
Cantor Fitzgerald Analyst forecast on SRPT
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$21
Hold
-9.60%
Downside
Reiterated
03/16/26
Cantor Fitzgerald Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sarepta Therapeutics

3 Months
xxx
Success Rate
22/38 ratings generated profit
58%
Average Return
+7.42%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 57.89% of your transactions generating a profit, with an average return of +7.42% per trade.
1 Year
Yun ZhongWedbush
Success Rate
14/21 ratings generated profit
67%
Average Return
+12.04%
Copying Yun Zhong's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +12.04% per trade.
2 Years
xxx
Success Rate
10/21 ratings generated profit
48%
Average Return
+8.91%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 47.62% of your transactions generating a profit, with an average return of +8.91% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SRPT Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
3
4
5
13
12
Buy
6
9
8
8
4
Hold
20
22
23
31
21
Sell
5
7
6
11
7
Strong Sell
5
7
4
6
3
total
39
49
46
69
47
In the current month, SRPT has received 16 Buy Ratings, 21 Hold Ratings, and 10 Sell Ratings. SRPT average Analyst price target in the past 3 months is 21.33.
Each month's total comprises the sum of three months' worth of ratings.

SRPT Financial Forecast

SRPT Earnings Forecast

Next quarter’s earnings estimate for SRPT is $0.98 with a range of -$0.76 to $2.85. The previous quarter’s EPS was -$3.93. SRPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.
Next quarter’s earnings estimate for SRPT is $0.98 with a range of -$0.76 to $2.85. The previous quarter’s EPS was -$3.93. SRPT beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.

SRPT Sales Forecast

Next quarter’s sales forecast for SRPT is $474.74M with a range of $310.20M to $727.92M. The previous quarter’s sales results were $442.93M. SRPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.
Next quarter’s sales forecast for SRPT is $474.74M with a range of $310.20M to $727.92M. The previous quarter’s sales results were $442.93M. SRPT beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year SRPT has Performed in-line its overall industry.

SRPT Stock Forecast FAQ

What is SRPT’s average 12-month price target, according to analysts?
Based on analyst ratings, Sarepta Therapeutics Inc.’s 12-month average price target is 21.33.
    What is SRPT’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for SRPT, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is SRPT a Buy, Sell or Hold?
        Sarepta Therapeutics Inc. has a consensus rating of Hold which is based on 7 buy ratings, 13 hold ratings and 5 sell ratings.
          What is Sarepta Therapeutics Inc.’s price target?
          The average price target for Sarepta Therapeutics Inc. is 21.33. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $38.00 ,the lowest forecast is $5.00. The average price target represents -8.18% Decrease from the current price of $23.23.
            What do analysts say about Sarepta Therapeutics Inc.?
            Sarepta Therapeutics Inc.’s analyst rating consensus is a Hold. This is based on the ratings of 25 Wall Streets Analysts.
              How can I buy shares of SRPT?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.